Cure
Overview
The latest longevity biotech funding news, updated monthly—tracking major rounds and non-dilutive awards of $10M or more in 2026.
This tracker covers capital raised by longevity and geroscience companies in 2026, including equity rounds and non-dilutive awards. Partnership deal values (milestone payments and royalties) are noted where relevant but are not counted as capital raised.
June 2026
Reservoir Neuroscience
Date: June 17 Series: Seed Amount: $3M Therapeutic Area: Aging brain, neurodegenerative disease Modality: Small molecules Notable Investors: Dolby Family Ventures; SV Health Investors; Kizoo Technology Capital
Reservoir Neuroscience has raised roughly $9 million to date, including a $3 million seed extension from Dolby Family Ventures and SV Health Investors that closed in June 2026, following a $4 million financing led by Kizoo Technology Capital in January 2024. The San Francisco Bay Area-based drug discovery biotech is focused on repairing the blood-brain barrier and improving blood vessel health to treat the aging brain and neurodegenerative diseases. Rather than targeting traditional proteins like amyloid and tau, Reservoir is looking at age-related vascular damage and neuroinflammation as potential early drivers of cognitive decline. The company uses a proprietary human vascular organ-on-a-chip platform to study how blood vessels change with age and identify potential new drug candidates.
Gero
Date: June 17 Series: Venture financing (undisclosed round) Amount: $17M (bringing total equity funding to $34M) Therapeutic Area: Aging biology and age-related chronic diseases Modality: AI-driven target discovery platform and small-molecule drug development Notable Investors: Melnichek Investments; pharmaceutical and technology sector investors Singapore- and San Francisco-based Gero raised $17M in new financing to advance its AI-powered platform for discovering medicines that slow aging and treat age-related diseases. The company's "physics-first" approach combines artificial intelligence with longitudinal human health data to identify biological mechanisms that drive aging and uncover drug targets shared across multiple chronic diseases. The proceeds are said to support advancement of Gero's proprietary pipeline and expansion of its pharmaceutical partnerships, following a collaboration with Chugai Pharmaceutical, a member of the Roche Group, worth up to $250M in milestone payments plus royalties.
NewLimit
Date: June 2 Series: Series C Amount: $435M Therapeutic Area: Aging biology, liver disease, and age-related metabolic disorders Modality: Epigenetic reprogramming mRNA therapeutics delivered via lipid nanoparticles (LNPs) Notable Investors: Founders Fund (lead); Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman & Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others
South San Francisco-based NewLimit closed a $435 million Series C to advance its first epigenetic reprogramming medicine into human clinical trials. The company's lead program uses lipid nanoparticle-delivered mRNA encoding proprietary transcription factors to restore youthful function in aging liver cells without changing cell identity. Preclinical studies showed the therapy reversed cellular aging in old human liver cells, restored liver regeneration in aged mice, and increased resilience to alcohol-related liver injury. The financing will support the company's first human clinical trial, expected to begin in 2027, initially targeting metabolic liver disease with plans to expand into additional age-related conditions.
May 2026
Retro Biosciences
Date: May 22 Series: Financing round (initial close) Amount: Undisclosed (at a $1.8B pre-money valuation) Therapeutic Area: Aging biology, Alzheimer's disease, and age-related diseases Modality: Small molecules, cell therapy, tissue reprogramming, AI-enabled protein engineering, and iPSC-derived stem cell therapies Notable Investors: 4P Capital (lead); additional investors not disclosed
San Francisco-based Retro Biosciences announced the initial close of a new financing round at a $1.8 billion pre-money valuation to advance its pipeline of therapies targeting the underlying biology of aging. The company's lead candidate, RTR242, a first-in-class oral therapeutic designed to restart autophagy, advanced into a Phase 1 clinical trial, progressing from indication selection to first human dosing in 15 months.The financing will support continued development of RTR242 and multiple additional first-in-human programs planned for 2026 and 2027 across the company's portfolio of cell therapy, tissue reprogramming, and AI-enabled protein engineering programs.
April 2026
Nula Therapeutics
Date: April 16 Series: ARPA-H PROSPR Award (non-dilutive) Amount: Up to $20M Therapeutic Area: Metabolic dysfunction, metabolic dysfunction-associated steatohepatitis (MASH), neurodegeneration, and age-related diseases Modality: Small molecules targeting the nuclear envelope Notable Investors: U.S. Advanced Research Projects Agency for Health (ARPA-H); backed by Apollo Health Ventures
New York-based Nula Therapeutics launched with an award of up to $20 million from ARPA-H's PROactive Solutions for Prolonging Resilience (PROSPR) program, bringing the company's total funding to more than $30 million. Nula is developing a new class of small-molecule medicines to restore nuclear envelope function, a key regulator of gene expression and cellular health implicated in aging and chronic disease. The funding will support a Phase 1b clinical trial of its lead candidate, NLT-101, in metabolic dysfunction planned for Q4 2026, as well as a parallel ARPA-H-funded clinical research program evaluating its potential to improve healthspan, intrinsic capacity, and functional resilience.
Life Biosciences
Date: April 8 Series: Series D Amount: $80M Therapeutic Area: Ophthalmology and age-related diseases Modality: Partial epigenetic reprogramming gene therapy Notable Investors: Fully subscribed round; investors not disclosed
Boston-based Life Biosciences closed an $80M Series D financing to advance its cellular rejuvenation platform and support its first-in-human clinical program. The financing will fund the Phase 1 clinical trial of ER-100, an AAV-based gene therapy for optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The proceeds will also support continued development of the company's Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications and extend operations into the second half of 2027.
February 2026
Cambrian Bio
Date: February 24 Series: Non-dilutive funding (ARPA-H PROSPR award) Amount: Up to $30.8M Therapeutic Area: Healthy aging and age-related functional decline Modality: Selective mTORC1 inhibitor Notable Investors: Advanced Research Projects Agency for Health (ARPA-H)
New York-based Cambrian Bio has been awarded up to $30.8 million through ARPA-H's PROactive Solutions for Prolonging Resilience (PROSPR) program to advance its TORnado platform of selective mTORC1 inhibitors. According to the company, the platform is designed to preserve the healthspan benefits associated with mTOR inhibition while avoiding the side-effect liabilities linked to mTORC2 inhibition. Cambrian said the funding will support development of the platform as part of PROSPR's effort to explore new approaches for improving intrinsic capacity, a measure of physical and metabolic resilience that declines with age.
January 2026
Juvena Therapeutics
Date: January 12 Series: Series B Amount: $33.5M Therapeutic Area: Neuromuscular diseases, metabolic disease, and age-related tissue degeneration Modality: AI-enabled regenerative biologics (protein therapeutics) Notable Investors: Bison Ventures (lead); Eli Lilly and Company, Jefferson Life Sciences, Mubadala Capital, and Manta Ray
Redwood City, California-based Juvena Therapeutics closed a $33.5M Series B to advance its pipeline of regenerative biologics designed to restore tissue function. The financing will support development of its lead candidate, JUV-161, a first-in-class muscle-regenerating biologic that is in Phase 1 clinical trials for myopathic conditions after demonstrating the ability to enhance muscle regeneration, metabolism, and strength in preclinical studies. The company also plans to expand its AI-enabled discovery platform and pipeline of tissue-restorative therapies. The financing follows Juvena's research collaboration with Eli Lilly, which includes the potential for more than $650 million in milestone payments.
